Despite significant advances in endocrinology, there are still large unmet needs for effective and safe treatments, especially for rare endocrine and metabolic diseases. We acknowledge that there is a need for more research and development activities to provide better care for these patients and are building and rapidly advancing a pipeline of innovative peptides.

Therapeutic peptides are particularly well suited as drugs for endocrine diseases, because many hormones are peptides or proteins.

discovery and research Lead Optimization IND-Enabling Phase 1 Rare Endocrine Diseases Rare Metabolic Diseases AZP-3601 for Hypoparathyroidism AZP-3813 for Acromegaly AZP-3404 for Undisclosed Metabolic Indication
Our portfolio currently includes:
  • AZP-3601, a potential treatment for hypoparathyroidism
  • AZP-3813, a potential treatment for acromegaly
  • AZP-3404, which is undergoing indication prioritization work
With our team’s established expertise in therapeutic peptides, we aim to further expand and rapidly advance our pipeline of promising innovative peptides through global approval.
Scroll to Top